JP7209936B2 - Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法 - Google Patents

Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法 Download PDF

Info

Publication number
JP7209936B2
JP7209936B2 JP2019562565A JP2019562565A JP7209936B2 JP 7209936 B2 JP7209936 B2 JP 7209936B2 JP 2019562565 A JP2019562565 A JP 2019562565A JP 2019562565 A JP2019562565 A JP 2019562565A JP 7209936 B2 JP7209936 B2 JP 7209936B2
Authority
JP
Japan
Prior art keywords
comprises seq
seq
msln
domain
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019562565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519643A5 (enExample
JP2020519643A (ja
Inventor
ウェスチェ，ホルガー
ディー． レモン，ブライアン
ジェイ． オースティン，リチャード
ビー． ドゥブリッジ，ロバート
Original Assignee
ハープーン セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハープーン セラピューティクス，インク． filed Critical ハープーン セラピューティクス，インク．
Publication of JP2020519643A publication Critical patent/JP2020519643A/ja
Publication of JP2020519643A5 publication Critical patent/JP2020519643A5/ja
Priority to JP2022202550A priority Critical patent/JP2023103173A/ja
Application granted granted Critical
Publication of JP7209936B2 publication Critical patent/JP7209936B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019562565A 2017-05-12 2018-05-11 Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法 Active JP7209936B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022202550A JP2023103173A (ja) 2017-05-12 2022-12-19 Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762505747P 2017-05-12 2017-05-12
US62/505,747 2017-05-12
US201862657434P 2018-04-13 2018-04-13
US62/657,434 2018-04-13
PCT/US2018/032427 WO2018209304A1 (en) 2017-05-12 2018-05-11 Msln targeting trispecific proteins and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022202550A Division JP2023103173A (ja) 2017-05-12 2022-12-19 Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法

Publications (3)

Publication Number Publication Date
JP2020519643A JP2020519643A (ja) 2020-07-02
JP2020519643A5 JP2020519643A5 (enExample) 2021-07-26
JP7209936B2 true JP7209936B2 (ja) 2023-01-23

Family

ID=64095980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019562565A Active JP7209936B2 (ja) 2017-05-12 2018-05-11 Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法
JP2022202550A Pending JP2023103173A (ja) 2017-05-12 2022-12-19 Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022202550A Pending JP2023103173A (ja) 2017-05-12 2022-12-19 Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法

Country Status (9)

Country Link
US (1) US10730954B2 (enExample)
EP (1) EP3621648A4 (enExample)
JP (2) JP7209936B2 (enExample)
KR (1) KR20200026810A (enExample)
CN (2) CN115028727A (enExample)
AU (1) AU2018265860B2 (enExample)
BR (1) BR112019023856A2 (enExample)
CA (1) CA3063362A1 (enExample)
WO (1) WO2018209304A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN105051069B (zh) 2013-01-14 2019-12-10 Xencor股份有限公司 新型异二聚体蛋白
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3223845B1 (en) 2014-11-26 2021-05-19 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
CN107849148B (zh) 2015-05-21 2023-09-19 哈普恩治疗公司 三特异性结合蛋白质及使用方法
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
LT3461261T (lt) 2016-05-20 2025-08-25 Harpoon Therapeutics, Inc. Vienos grandinės kintamo fragmento cd3 surišantys baltymai
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
ES2875959T3 (es) 2016-10-07 2021-11-11 Tcr2 Therapeutics Inc Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
WO2018098354A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
CA3044729A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
CN113896792B (zh) 2017-05-12 2025-08-22 哈普恩治疗公司 间皮素结合蛋白质
EP3621648A4 (en) * 2017-05-12 2021-01-20 Harpoon Therapeutics, Inc. TRISPECIFIC PROTEINS MSLN AND METHOD OF USE
US20200270362A1 (en) * 2017-05-12 2020-08-27 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
KR102425983B1 (ko) 2017-10-13 2022-07-29 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
KR20210020903A (ko) 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
WO2021231969A1 (en) * 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind msln and cd3
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
TW202237653A (zh) * 2020-12-09 2022-10-01 美商詹努克斯治療有限公司 與經腫瘤活化之靶定trop2及效應細胞抗原之抗體相關之組合物及方法
WO2022125576A1 (en) * 2020-12-09 2022-06-16 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
CA3239553A1 (en) * 2021-12-10 2023-06-15 Arthur Fridman Human mesothelin binders
EP4458861A1 (en) * 2021-12-29 2024-11-06 Sichuan Huiyu Pharmaceutical Co., Ltd. Antibody targeting cd3, multispecific antibody, and uses thereof
WO2023134742A1 (zh) * 2022-01-14 2023-07-20 浙江道尔生物科技有限公司 一种三靶点抗肿瘤药物、其制备方法及其应用
WO2023153711A1 (ko) * 2022-02-10 2023-08-17 경북대학교 산학협력단 메소세린에 결합하는 펩타이드 및 이의 용도
US20230340128A1 (en) 2022-02-24 2023-10-26 Xencor, Inc. Anti-cd28 x anti-msln antibodies
JP2025508066A (ja) 2022-03-07 2025-03-21 ノビミューン エスアー 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体
EP4493592A1 (en) 2022-03-14 2025-01-22 LamKap Bio gamma AG Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
WO2023179740A1 (en) * 2022-03-25 2023-09-28 Shanghai Henlius Biotech , Inc. Anti-msln antibodies and methods of use
CN119768428A (zh) 2022-07-29 2025-04-04 酵活英属哥伦比亚有限公司 多价双特异性抗体构建体及其使用方法
JP2025002813A (ja) 2023-06-23 2025-01-09 セイコーエプソン株式会社 シート製造装置
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025082777A1 (en) * 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025132770A1 (en) * 2023-12-22 2025-06-26 Institut National de la Santé et de la Recherche Médicale Affitins for the treatment of cancer
WO2025163144A1 (en) * 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160340444A1 (en) 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU2764792A (en) 1991-10-04 1993-05-03 Iit Research Institute Conversion of plastic waste to useful oils
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1047770A1 (zh) 2000-02-24 2003-03-07 Xcyte Therapies, Inc. 细胞的同时刺激与浓缩
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
EP1448588A4 (en) 2001-10-23 2006-10-25 Psma Dev Company L L C ANTIBODIES AND MULTIMERS OF PSMA PROTEINS
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
AU2003224604B2 (en) 2002-01-28 2007-06-14 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (PSMA)
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
NZ540219A (en) 2002-11-07 2008-08-29 Univ Erasmus Fret probes and methods for detecting interacting molecules
PT2316852E (pt) 2002-11-08 2014-06-23 Ablynx Nv Anticorpos de domínio único estáveis
EP1558650A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
US20050042664A1 (en) 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
BRPI0511755A (pt) 2004-06-01 2008-01-02 Domantis Ltd composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
WO2006020258A2 (en) 2004-07-17 2006-02-23 Imclone Systems Incorporated Novel tetravalent bispecific antibody
US20080069772A1 (en) 2004-08-26 2008-03-20 Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum Treatment of transformed or infected biological cells
EP1634603A1 (de) 2004-08-26 2006-03-15 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von transformierten oder infizierten biologischen Zellen
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
ATE414718T1 (de) 2005-01-05 2008-12-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US20060252096A1 (en) 2005-04-26 2006-11-09 Glycofi, Inc. Single chain antibody with cleavable linker
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
PL2444424T3 (pl) 2005-05-20 2019-01-31 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
EP3770174A1 (en) 2005-10-11 2021-01-27 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
WO2007062466A1 (en) 2005-11-29 2007-06-07 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
WO2007115230A2 (en) 2006-03-30 2007-10-11 University Of Medicine And Dentistry Of New Jersey A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
EP2069402A2 (en) 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
PT2520590T (pt) 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Domínio de ligação específico de espécies cruzadas
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
US20120039870A9 (en) 2007-09-07 2012-02-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
AU2009254501B2 (en) * 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
US20110177070A1 (en) 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
CA2738566C (en) 2008-10-01 2024-04-30 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
US9327022B2 (en) 2008-10-14 2016-05-03 National Research Council Of Canada BSA-specific antibodies
WO2010077643A1 (en) 2008-12-08 2010-07-08 Tegopharm Corporation Masking ligands for reversible inhibition of multivalent compounds
EP2210902A1 (en) 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
US10584181B2 (en) 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
PT2519543T (pt) 2009-12-29 2016-10-07 Emergent Product Dev Seattle Proteínas de ligação de heterodímero e suas utilizações
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
EP2550529B1 (en) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
JP5753903B2 (ja) 2010-08-24 2015-07-22 ロシュ グリクアート アーゲー 活性化可能な二重特異性抗体
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
JP2014500879A (ja) 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
WO2012131053A1 (en) 2011-03-30 2012-10-04 Ablynx Nv Methods of treating immune disorders with single domain antibodies against tnf-alpha
CA2832540C (en) 2011-04-08 2020-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
WO2013036130A1 (en) 2011-09-09 2013-03-14 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
CN108034006A (zh) 2012-01-13 2018-05-15 乌利班-马克西姆利安大学 双抗原诱导的双功能互补作用
WO2013110531A1 (en) 2012-01-23 2013-08-01 Ablynx Nv Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
SMT201700467T1 (it) 2012-02-24 2017-11-15 Abbvie Stemcentrx Llc Modulatori di dll3 e metodi di uso
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
EP2820047B1 (en) 2012-03-01 2018-04-25 Amgen Research (Munich) GmbH Long life polypeptide binding molecules
US9975962B2 (en) 2012-03-30 2018-05-22 Bayer Healthcare Llc Thrombin/plasmin-regulated antibodies that bind TFPI
CA2870545A1 (en) 2012-04-20 2013-10-24 Emergent Product Development Seattle, Llc Cd3 binding polypeptides
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
CN104583236A (zh) 2012-08-31 2015-04-29 阿尔金-X有限公司 高度多样的组合抗体文库
KR101963231B1 (ko) 2012-09-11 2019-03-28 삼성전자주식회사 이중특이 항체의 제작을 위한 단백질 복합체 및 이를 이용한 이중특이 항체 제조 방법
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014052064A1 (en) * 2012-09-27 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US20160015749A1 (en) 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
ES2746240T3 (es) 2013-03-13 2020-03-05 Health Research Inc Composiciones y procedimientos para la utilización de receptores de células T recombinantes para el reconocimiento directo de un antígeno tumoral
US20140308285A1 (en) * 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
EP2970484B2 (en) 2013-03-15 2022-09-21 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
UY35484A (es) 2013-03-15 2014-10-31 Amgen Res Munich Gmbh Molécula de unión de cadena simple que comprenden ABP de extremo N
BR112016001611B1 (pt) 2013-07-25 2024-01-09 Cytomx Therapeutics, Inc Anticorpo ativável multiespecífico, uso terapêutico do mesmo, molécula de ácido nucleico isolada, vetor e método para produzir um anticorpo ativável multiespecífico
US9688727B2 (en) 2013-09-24 2017-06-27 University Of Washington Desmoglein 2 (DSG2) binding proteins and uses therefor
WO2015044386A1 (en) 2013-09-26 2015-04-02 Ablynx Nv Bispecific nanobodies
DK3089994T3 (da) 2013-12-30 2022-07-04 Epimab Biotherapeutics Inc Fabs-in-tandem-immunglobulin og anvendelser deraf
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
SG10201913324PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
MX384418B (es) * 2014-07-31 2025-03-14 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido.
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
CN105471609B (zh) 2014-09-05 2019-04-05 华为技术有限公司 一种用于配置业务的方法和装置
SG11201701599UA (en) 2014-09-05 2017-03-30 Janssen Pharmaceutica Nv Cd123 binding agents and uses thereof
AU2015323313B2 (en) 2014-09-25 2021-04-01 Amgen Inc. Protease-activatable bispecific proteins
CN107109368A (zh) 2014-10-07 2017-08-29 塞勒克提斯公司 用于调节car诱导的免疫细胞活性的方法
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
EA038407B1 (ru) 2015-02-05 2021-08-24 Янссен Вэксинс Энд Превеншн Б.В. Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения
MX382212B (es) 2015-04-22 2025-03-13 Agbiome Inc Genes pesticidas y metodos de uso.
CN107709363A (zh) 2015-05-01 2018-02-16 基因泰克公司 掩蔽抗cd3抗体和使用方法
JP6867302B2 (ja) 2015-05-21 2021-04-28 フル スペクトラム ジェネティクス， インコーポレイテッド タンパク質の特徴を改善する方法
CN108271390A (zh) 2015-06-03 2018-07-10 农业生物群落股份有限公司 杀虫基因和使用方法
DK3313874T3 (da) 2015-06-26 2021-05-03 Univ Southern California Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
WO2017025698A1 (en) 2015-08-11 2017-02-16 Queen Mary University Of London Bispecific, cleavable antibodies
CN106519037B (zh) 2015-09-11 2019-07-23 科济生物医药（上海）有限公司 可活化的嵌合受体
AU2016349482A1 (en) 2015-11-05 2018-05-24 City Of Hope Methods for preparing cells for adoptive T cell therapy
WO2017087789A1 (en) 2015-11-19 2017-05-26 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US10093694B2 (en) 2016-02-03 2018-10-09 Guangzhou Kangrui Biological Pharmaceutical Technology Co, Ltd. Compounds for treating eye disorders or diseases
MX2018010824A (es) 2016-03-08 2019-05-15 Maverick Therapeutics Inc Proteinas de union inducibles y metodos de uso.
LT3461261T (lt) 2016-05-20 2025-08-25 Harpoon Therapeutics, Inc. Vienos grandinės kintamo fragmento cd3 surišantys baltymai
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
ES2875959T3 (es) * 2016-10-07 2021-11-11 Tcr2 Therapeutics Inc Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
WO2018071777A1 (en) 2016-10-14 2018-04-19 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
CA3044729A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
WO2018098354A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2018136725A1 (en) 2017-01-19 2018-07-26 Harpoon Therapeutics, Inc. Innate immune cell inducible binding proteins and methods of use
WO2018160671A1 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Targeted checkpoint inhibitors and methods of use
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
US20200115461A1 (en) 2017-05-03 2020-04-16 Harpoon Therapeutics, Inc. Compositions and methods for adoptive cell therapies
EP3621648A4 (en) 2017-05-12 2021-01-20 Harpoon Therapeutics, Inc. TRISPECIFIC PROTEINS MSLN AND METHOD OF USE
CN113896792B (zh) 2017-05-12 2025-08-22 哈普恩治疗公司 间皮素结合蛋白质
KR102425983B1 (ko) 2017-10-13 2022-07-29 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US20210269530A1 (en) 2018-05-14 2021-09-02 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
EP3794044A4 (en) 2018-05-14 2022-02-16 Harpoon Therapeutics, Inc. DOUBLE BINDING UNIT
KR20210020903A (ko) 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160340444A1 (en) 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use

Also Published As

Publication number Publication date
JP2023103173A (ja) 2023-07-26
CN110913908B (zh) 2022-05-27
AU2018265860A1 (en) 2020-01-16
CN110913908A (zh) 2020-03-24
EP3621648A1 (en) 2020-03-18
AU2018265860B2 (en) 2022-08-11
BR112019023856A2 (pt) 2020-06-09
US20180327508A1 (en) 2018-11-15
CA3063362A1 (en) 2018-11-15
CN115028727A (zh) 2022-09-09
EP3621648A4 (en) 2021-01-20
JP2020519643A (ja) 2020-07-02
WO2018209304A1 (en) 2018-11-15
US10730954B2 (en) 2020-08-04
KR20200026810A (ko) 2020-03-11

Similar Documents

Publication Publication Date Title
JP7209936B2 (ja) Ｍｓｌｎ標的三重特異性タンパク質及びその使用方法
JP7385707B2 (ja) 三重特異性タンパク質と使用方法
JP7659669B2 (ja) Ｄｌｌ３結合タンパク質および使用方法
JP7348349B2 (ja) Ｂ細胞成熟抗原結合タンパク質
JP7317185B2 (ja) メソテリン結合タンパク質
JP2020501532A (ja) 前立腺特異的膜抗原結合タンパク質
JP2024523003A (ja) Ｄｌｌ３標的化三重特異性タンパク質およびそれらの使用方法
US20200270362A1 (en) Msln targeting trispecific proteins and methods of use
WO2022256498A1 (en) Msln targeting trispecific proteins and methods of use
JP2024520727A (ja) Ｂｃｍａ標的化三重特異性タンパク質およびその使用
JP2023502876A (ja) がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質
WO2025085761A1 (en) Dll3 targeting trispecific proteins and methods of use
CN118159554A (zh) Dll3靶向三特异性蛋白及其使用方法
HK40088389B (zh) 针对folr1的双特异性抗体及其用途
HK40088389A (zh) 针对folr1的双特异性抗体及其用途
EA040342B1 (ru) Связывающие мезотелин белки

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221117

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221216

R150 Certificate of patent or registration of utility model

Ref document number: 7209936

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150